ANDA 205379, held by Accord Hlthcare. Esomeprazole Sodium.
As of Nov 16, 2026, ANDA 205379 (Esomeprazole Sodium), held by Accord Hlthcare, was first approved by FDA on Sep 25, 2015, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Esomeprazole SodiumEQ 40MG BASE/VIAL · injectable;intravenous | Esomeprazole Sodium | Discontinued |
| Apr 17, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 17, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 17, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 17, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 17, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 17, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 25, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters